Selexis and NexImmune expand long-standing research collaboration

Geneva, Switzerland-based cell-line company Selexis and NexImmune (Nasdaq: NEXI), a T cell specialist, has signed a service agreement to develop cell lines targeting rare cancers and autoimmune diseases.

Selexis, which is a subsidiary of Japanese conglomerate JSR Corporation (TYO: 4185), will work with the American firm to advance two human leukocyte antigens (HLA) with the aim of expanding treatments to reach more patients.

NexImmune will use Selexis’ SUREtechnology platform, a suite of cell line development technologies which are designed to create cell lines in less time and at a lower cost.